JNJ · Full Picture

JOHNSON & JOHNSON — the full picture

Earnings window · 2026-07-23 to 2026-11-09

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Accrued Legal and Regulatory · Regulatory action & investigationsPriority 92
    -2.7% liability; 3 sources (news, sec_filing, transcript); 3 forward row(s); structured_verified
    Expenses associated with the Firefly Bio transaction and Cell BioMedicines collaboration, plus proposed talc litigation resolution, amounted to approximately $7 billion in the quarter.
  2. Revenue Performance and Mix · Revenue growth & mixPriority 90
    +0.9% revenue; 4 sources (news, press_release, sec_filing, transcript); 3 forward row(s); structured_verified
    BofA projects J&J third-quarter sales of $25.5 billion and EPS of $2.53.
  3. Talc Litigation Settlement · Litigation & settlementsPriority 86
    -10.9% operating_income; 4 sources (news, press_release, sec_filing, transcript); 6 forward row(s); structured_verified
    Q3 2026 earnings per share of $0.09 reflects a one-time special charge for the proposed talc litigation resolution, the acquisition of Firefly Bio, Inc., and the strategic collaboration with Sail Biomedicines.
  4. Immunology Competition Pressure · Competition & market sharePriority 73
    -7.4% revenue (realized); 3 sources (news, sec_filing, transcript); 1 forward row(s); quote_verified
    STELARA sales were $1,396 million for the fiscal six months ended June 28, 2026 versus $3,278 million prior year, a total decline of 57.4% and an operational decline of 58.7%.
  5. Acquisition / Partnership / Divestiture · M&A and divestituresPriority 70
    -0.3% cash; 2 sources (news, press_release); 9 forward row(s); quote_verified
    Johnson & Johnson secured an exclusive option to acquire Sail Biomedicines for an additional $2.58 billion, bringing the potential total value to $3.5 billion.
  6. Guidance and Outlook · Guidance & outlookPriority 70
    -3.4% net_income; 3 sources (news, press_release, transcript); 16 forward row(s); quote_verified
    Johnson & Johnson increased October 2026 estimated reported sales guidance to $101.0 billion – $101.4 billion with a midpoint of $101.2 billion, a 7.2% – 7.6% change vs prior year and 7.4% at the midpoint.
  7. Quarterly Earnings Performance · UnclassifiedPriority 69
    -21.4% net_income (realized); 2 sources (news, press_release); quote_verified
    Q3 2026 adjusted net earnings: $6,339 million versus $6,801 million in 2025, down (6.8)%.
  8. Segment Profitability · Operating income & profitabilityPriority 66
    -29.6% operating_income (realized); structured_verified
    Consolidated earnings before provision for taxes on income for the fiscal six months of 2026 was $12.7 billion representing 25.8% of sales as compared to $20.1 billion in the fiscal six months of 2025 representing 44.1% of sales.
  9. Headcount / Restructuring · Restructuring & impairmentPriority 65
    -4.7% operating_income; 2 sources (news, sec_filing); 3 forward row(s); structured_verified
    In the fiscal second quarter of 2026, the Company initiated a supply chain restructuring program primarily in the Innovative Medicine segment to exit certain manufacturing locations; the program is expected to be substantially complete by the end of 2029 with estimated costs between $650 million and $750 million.
  10. Operating Expense Trends · Operating expenses (SG&A)Priority 65
    -19.9% operating_income (realized); 2 forward row(s); quote_verified
    Research and development investment was approximately $4.7 billion, or 18.3% of sales, including $1 billion related to the acquisition of Firefly Bio.
  11. Liquidity and Cash Position · Liquidity & cash positionPriority 62
    +5.5% cash (realized); 2 sources (sec_filing, transcript); 1 forward row(s); structured_verified
    As of June 28, 2026, the Company had cash, cash equivalents and marketable securities of approximately $20.8 billion and had approximately $49.0 billion of notes payable and long-term debt for a net debt position of $28.2 billion compared to prior year fiscal second quarter net debt of $31.9 billion.
  12. MedTech Product And Procedure Trends · UnclassifiedPriority 61
    3 sources (news, press_release, sec_filing); 1 forward row(s); quote_verified
    Johnson & Johnson announced MONARCH QUEST 3, advancing robotically-assisted bronchoscopy.

Threads by pillar

Revenue & Demand Priority 95 · 11 threads

Costs & Margins Priority 79 · 4 threads

Capital & Balance Sheet Priority 76 · 6 threads

Strategy & Portfolio Priority 82 · 11 threads

Legal, Regulatory & Policy Priority 96 · 7 threads

Guidance & Outlook Priority 70 · 1 thread

Macro & Market Conditions Priority 83 · 7 threads

Management & Governance Priority 30 · 1 thread

Unclassified Priority 96 · 5 threads

Expected impact by metric

metricforward netforward grossrealized
operating_income-18.9%+18.9%-52.7%
cash+4.1%+4.8%-6.6%
liability-4.4%+4.4%—
revenue+3.9%+3.9%+30.3%
net_income-3.4%+3.4%-54.0%
assets+0.2%+3.2%+12.6%
margin-0.5%+0.5%-9.5%